Emel Mutlu Ozkan

6PUBLICATIONS
43CO-AUTHORS
Liquid biopsiesPredictive and prognostic markersInnate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 08, 2026
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

|Apr 14, 2026
Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab.

Gözde Ağdaş, Duygu Bayir, Elif Şahin

|Feb 21, 2026
The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer.

Muhammet Cengiz, Oktay Bozkurt, Ayşe Nuransoy Cengiz

|Jan 28, 2026
Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer.

Ayse Nuransoy Cengiz, Oktay Bozkurt, Muhammet Cengiz

|Jan 28, 2026
Dynamic Immune-Nutritional Indices as Powerful Predictors of Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Emel Mutlu Ozkan, Ibrahim Karadag, Mevlude Inanc

|Dec 19, 2025
Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach.

Emel Mutlu, Mevlüde İnanç

Pageof 1

Frequent Collaborators

4 joint publications

Erkam Kocaaslan

4 joint publications

Metin Ozkan

4 joint publications

Devrim Cabuk

4 joint publications

Duygu Bayir